ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 452

Effectiveness and Tolerance Infiltration Intraarticular Corticosteroid According to Dose

Daniele F. Pereira1, Rita N.V. Furtado2, Natalia P. Machado3 and Jamil Natour4, 1Disciplina de Reumatologia, Universidade Federal de São Paulo (UNIFESP), São Paulo, Brazil, 2Rheumatology, Universidade Federal de São Paulo, São Paulo, Brazil, 3Disciplina de Reumatologia, Universidade Federal de São Paulo, São Paulo, Brazil, 4Rheumatology Division, Universidade Federal de São Paulo, São Paulo, Brazil

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Corticosteroids and rheumatoid arthritis, treatment

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy

Session Type: Abstract Submissions (ACR)

Background/Purpose: The optimal dose of corticosteroid to be used in intraarticular injection is not well established. The objective of this study is to compare the effectiveness and tolerance in the medium-term between small and large doses of triamcinolone hexacetonide (TH) used in intraarticular injection (IAI) of medium size joints of patients with rheumatoid arthritis (RA).

Methods: A controlled, randomized, prospective, double-blind study was carried out  in patients with RA. It was evaluated 60 wrists joints (representing medium size joints) from the outpatient clinic at the Rheumatology Division UNIFESP, Brazil. Inclusion criteria were: patients with established RA, age between 18 and 65 years, disease modifying anti-rheumatic drugs (DMARDs) stable for at least 3 months, synovitis in wrist with pain visual analogic scale (VAS) between 4 and 8cm. Patients with overlap syndromes, polyarticular synovitis, diabetes mellitus or uncontrolled hypertension and those with suspected local or systemic infection were excluded. Patients were randomized (Clapboard randomization) in two groups of 30 patients each: group 1 (high dose) was injected with 40mg (2ml) of TH and group 2 (low dose) was injected 20mg (1ml). Only one joint was injected per patient (IAI blindly). Evaluation was conducted by a blinded observer at five times: baseline (T0), one week (T1), four (T4), eight (T8) and twelve (T12) weeks and the following assessment instruments were used: visual analogue scale for pain and swollen (swelling) (VAS 0-10cm); wrist goniometry; chronic disease activity index (CDAI). Side effects and related events were reported in a medical questionnaire. The level of statistical significance was 5%.

Results:  A total of 60 patients were injected (50 women, 37 white). Mean age was 50.0 (± 12.5) years old in the high dose group and 51.7 (± 11.6) in the low dose group (p=0.586). No statistically significant difference between groups was observed for VAS for pain, VAS for swelling, CDAI, HAQ and goniometry. But all study variables improved over time in both groups and particularly T0 improved statistically significant from all other times for VAS for pain and swelling,CDAI  and HAQ (all p<0.008). Wrist goniometry was statistically different in some periods and only in the high dose group was the improvement maintained until T12 (p<0.004). There was a significant increase of  the use of nonsteroidal anti-inflamamatory (NA) and analgesics necessary to relieve pain soon after IAI, but this use decreased after T1 equally between groups (p<0.692). Very few adverse effects and related events were reported in both groups (p=0.195).

Conclusion: There is no difference  in effectiveness of the intraarticular injection  between high and low doses of TH  used  in medium size joints of patients with RA.


Disclosure:

D. F. Pereira,
None;

R. N. V. Furtado,
None;

N. P. Machado,
None;

J. Natour,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/effectiveness-and-tolerance-infiltration-intraarticular-corticosteroid-according-to-dose/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology